Supplemental Methods

Quality Control
All measurements follow a strict quality control process in the CARDIA study. Spirometry data was measured using a Collins Survey 8-liter water sealed spirometer and an Eagle II Microprocessor (Warren E. Collins, Inc., Braintree, MA). Standard procedures of the American Thoracic Society were followed at all examinations. E1 E2 E3 E4 E5 Daily checks for leaks, volume calibration with a 3-liter syringe and weekly calibration in the 4-7 liter range were undertaken to minimize methodological artifacts between exams.
Seated blood pressure was measured 3 times after 5 min of rest with the average of the last 2 measurements used in analysis. Concurrent use of β-blocker medications was also obtained from self-reports, with an examination of medication bottles when available, at each time period.
Urinary albumin excretion was estimated from a single untimed urine sample by measuring the albumin creatinine ratio or A/kC as mg of albumin per g of creatinine, where the factor k corrects for the relatively greater average daily creatinine excretion in men and blacks than in women and whites. The values of k are 0.68 in white men, 0.68*0.88 in black men, 0.88 in black women, and 1 in white women. E6 Warram et al. showed a high correlation between a single untimed urine and the value obtained in 24 hour urine collection.
E7
Urine creatinine concentrations at each examination were measured by nephelometry according to National Institute of Standards and Technology standards (Linco Research, Inc., St Louis, MO, USA). E8 Albumin was measured in year 10 samples by nephelometry based on monoclonal antibodies to human albumin (assay sensitivity, 0.45 mg/liter). Note 1: All data were obtained at CARDIA Y5 except change in BMI, rapid FEV1 or FVC decline, urinary albumin creatinine ratio, and systemic hypertension. Systemic hypertension, defined as systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg or taking antihypertensive medication at or before Y10 (i.e. at Y0, Y2, Y5, Y7 or Y10). Urinary albumin creatinine ratio was not measured at Y5 and was defined by ratio of ≥ 25 mg/g at Y10, after race and sex correction. Change in BMI was defined between Y0 to Y5. Note 2: Self-reported physical activity in the past year at Y5 was defined on a 5 point Likert scale. High level of activity is defined as more than moderately active (4 and 5 on 5 point Likert scale). Key: BMI -Body mass index; FEV1-Forced expiratory volume in 1 second; FVC-Forced vital capacity 16/3052 (0.5%) *Albumin excretion rate was measured using the formula albumin/(ĸ x creatinine); where ĸ adjusts for race and sex differences in typical daily creatinine excretion.
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Note 1: Moderate and severe eUAE correspond to microalbuminuria and macroalbuminuria terms respectively. Note 2: The Y20 or Y25 value was achieved by using the following probability calculation: Probability (A or B) = Probability(A) + Probability(B) -Probability(A and B) Table 3 of the main text of the manuscript plus additional exploratory covariates. Covariates used in the adjusted model in Table 3 of the main text of the manuscript included sex, enlarged waist circumference, diabetes mellitus, age, race, height, current smoking status, pack-year smoking history, and physical activity (all measured at Y5); hypertension at or before Y10, change in BMI between Y0-Y5, and peak FEV1 or FVC. Additional exploratory covariates included change in BMI between Y0-Y20, sum of smoking pack years over Y0-Y20, fasting blood glucose levels at Y7, and self-reported asthma status at Y5. Glucose levels were not available at every CARDIA visit year, and thus blood glucose levels at Y7 were used. Note 2: Rapid decline was defined by the highest tertile of decline and compared to the lower two tertiles. Rapid FEV1 decline was defined by ≥52 ml/year. Rapid FVC decline was defined by ≥ 45.8 ml/year. Note 3: Incident eUAE was defined as the new occurrence of excretion at Y20 or Y25 examination visits (at a mean age of 45 or 50 years) without antecedent excretion. Prevalent eUAE was defined as excretion at CARDIA Y20 and/or Y25, irrespective of antecedent excretion. Persistent eUAE was defined as excretion at Y25 plus at one or more measurements at Y10, Y15, or Y20. Note 4: * signifies p≤ 0.05 Key: FVC-Forced vital capacity; FEV1-Forced expiratory volume in 1 second; C.I. -Confidence Interval; O.R. -Odds Ratio
